What’s On Your List Of Penny Stocks To Buy Right Now?
In the stock market today news headlines are already abuzz about what the Fed’s next move will be. But will that dramatically impact penny stocks, in general? Probably not. This is the beauty of trading small-cap and micro-cap stocks.
They tend to move without direct intervention from the broader markets. That isn’t to say that certain penny stocks won’t be impacted. But for the most part, if there are trending penny stocks today, that trend has/will have much more to do with the individual stock/company than the rest of the stock market.
- 4 Penny Stocks To Watch This Week Under $3
- Best Penny Stocks On Robinhood To Watch Right Now
- Will These Be On Your Penny Stocks To Buy Or Sell List This Week?
The important part is making sense of the information you find. Sure, we preach due diligence, but what does that mean and how do you use it? You might be a great note-taker but when it comes to the actual test, how do you use the notes you took to pass with flying colors? It all comes down to practice and building your strategy.
How To Find The Best Penny Stocks To Buy
There’s no simple “If, then” that says “if there’s penny stock news, then shares will rise”. It’s not just news nor is it filings that determine the overall direction of a stock. There’s also market sentiment, the actual contents of the news/filing, momentum, and a little speculation doesn’t hurt either.
Understanding how to navigate it all at the same time is the important part. If you’re looking to understand the basics of penny stocks, we’ve got access to our ebook and you get it free for simply subscribing to PennyStocks.com.
Already know the basics? Time to look for some trending in the market. Here’s a quick list of stocks to watch. But will they be the best penny stocks to buy right now? Put that learning to work because that choice is up to you.
Diffusion Pharmaceuticals (DFFN)
Another one of the penny stocks to watch after earnings is Diffusion Pharmaceuticals (DFFN Stock Report). The company reported its Q1 results this week and gave a business update. Remember, earlier this month Diffusion announced that the U.S. FDA will accelerate its review of the company’s clinical development plan using low oxygen levels.
Diffusion’s COVID-19 program is a cooperative research effort with the University of Virginia Health System and the Integrated Translational Research Institute of Virginia. David Kalergis, chief executive officer of Diffusion explained, “We continue to work with hospital and regulatory authorities in the U.S. , and now also in Eastern Europe , to forge the fastest possible pathway to approval for TSC in the treatment of COVID-19 patients.”
Diffusion believes that TSC’s novel oxygen-enhancing mechanism of action could provide an important new treatment option for this life-threatening condition. The three-part program will focus on enhanced blood oxygenation in patients admitted to an intensive care unit and on reduction in patient progression to the ICU. After essentially summing up the major achievements for the quarter and discussing the plan after a response from the FDA sentiment grew bullish during the week. DFFN stock continued to push higher in a trend that has now lasted for 5 consecutive sessions.
Shares of data company Inpixon (INPX Stock Report) are pushing higher this week. It came on the heels of two key developments from the company. First, Inpixon announced Q1 results for 2020. The company realized a 32% increase in revenue year over year. However, Inpixon also realized a smaller gross margin for the quarter; 72% compares to 75% from the first quarter in 2019.
Nadir Ali , CEO of Inpixon , commented, “With the help and dedication of all of our employees who have had to work harder than ever to balance work responsibilities with the challenges of family life during extremely difficult times, we have been able to seamlessly continue our business operations remotely, with minimal impact on our day-to-day operations. The company followed up with another announcement on the upcoming availability of Workplace Readiness Dashboards™.
“Businesses are asking for Inpixon’s help in facilitating back-to-work transitions in a time when understanding what is happening within our indoor spaces has never been more important,” noted Nadir Ali , Inpixon CEO. Thanks to these latest developments in light of the COVID-19 pandemic, INPX stock has started to climb higher this week.
Helius Medical Technologies (HSDT)
Biotech penny stocks are a hot ticket item right now. That’s not only from rising interest in coronavirus vaccine stocks but also “getting back to the basics”. Just because a company focuses on something other than COVID-19 doesn’t mean they aren’t working to create life-changing treatments. Needless to say, Helius Medical Technologies (HSDT Stock Report) falls into the second category and the market has reacted positive to its latest update.
Helius announced that it has received Breakthrough Designation for its PoNS™ device. It will be utilized as a potential treatment for gait deficit due to symptoms of Multiple Sclerosis, to be used as an adjunct to a supervised therapeutic exercise program. The Breakthrough Devices Program is a voluntary program for certain medical devices and device-led combination products that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
“We are extremely pleased to receive this designation for our PoNS device,” said Philippe Deschamps, the Company’s CEO. “We look forward to working with FDA to process our application, with the ultimate goal of bringing our innovative technology to the aid of patients suffering with gait deficit due to MS-related symptoms, by providing them with a non-drug, non-implantable treatment that has the potential to significantly improve their ability to walk.”